We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.11 | 0.25% | 44.10 | 13,607 | 13:59:54 |
From May 2019 to May 2024
By Colin Kellaher
Bristol-Myers Squibb Co. on Wednesday said the European Commission approved Zeposia for the treatment of adults with relapsing remitting multiple sclerosis with active disease.
The New York biopharmaceutical company said Zeposia, an oral once-daily medication, becomes the only EC-approved sphingosine-1-phosphate receptor modulator for such patients with active disease.
Bristol-Myers, which in March received U.S. Food and Drug Administration for Zeposia for adults with relapsing forms of multiple sclerosis, is also developing the drug for additional immune-inflammatory indications, including ulcerative colitis and Crohn's disease.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 27, 2020 07:32 ET (11:32 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
